Key result
Serum periostin levels were significantly higher in patients with allergic bronchopulmonary aspergillosis (85.55 ng/mL) compared to severe asthma with fungal sensitization (50.99 ng/mL; P<0.01).
Why the study?
Serum periostin is an indicator of Th2 inflammation in asthma, but its levels and diagnostic or monitoring value in allergic bronchopulmonary aspergillosis (ABPA) required investigation.
Can serum periostin levels differentiate allergic bronchopulmonary aspergillosis from severe asthma with fungal sensitization?
Observational (n=43)
Can serum periostin levels differentiate allergic bronchopulmonary aspergillosis from severe asthma with fungal sensitization?
Absolute Event Rate: 85.55% vs 50.99%
p-value: p=< 0.01
Serum periostin levels are elevated in ABPA compared to severe asthma with fungal sensitization and may serve as a useful biomarker for differential diagnosis.
May support periostin for differentiating ABPA from SAFS; hypothesis-generating and needs prospective validation before clinical adoption.
BACKGROUND: Serum periostin levels have been reported to be an indicator of Th2 inflammation in asthmatic patients. OBJECTIVE: This study aimed to investigate serum levels of periostin in patients with allergic bronchopulmonary aspergillosis (ABPA) and to evaluate its diagnostic and monitoring value in the disease. METHODS: Patients with ABPA (n = 19) and asthma (n = 24), including severe asthma with fungal sensitisation (SAFS, n = 11) and severe asthma without fungal sensitization (SAwFS, n = 13), were enrolled. Serum levels of periostin were analysed by enzyme-linked immunosorbent assay. Serum total IgE and Aspergillus fumigatus specific IgE, IgG were measured by ImmunoCAP. Levels of cytokines (IFN-γ, IL-4, IL-5, IL-8, IL-10, IL-13 and IL-17A) were measured by Meso Scale Discovery (MSD). RESULTS: Serum levels of periostin in ABPA patients (85.55 ng/mL, [68.28-166] ng/mL) were higher than those in SAFS (50.99 ng/mL, [32.02-71.80] ng/mL; P < 0.01). Among the analysed cytokines, IL-5 levels in ABPA (1.55 pg/mL, [0.96-3.33] pg/mL) were higher than those in SAFS (0.31 pg/mL, [0.26-0.56] pg/mL; P < 0.05) or SAwFS (0.34 pg/mL, [0.21-0.56] pg/mL; P < 0.01). Serum periostin levels was positively associated with total IgE levels (r = 0.319, P < 0.05), serum IL-5 levels (r = 0.484, P < 0.01) and blood eosinophil counts (r = 0.428, P < 0.05). In ROC analysis, the clinical reference value of periostin was 68.8 ng/mL for differential diagnosis of ABPA and SAFS, with the area under the curve (AUC) of 0.81. Longitudinally, serum periostin levels did not change significantly after treatment in ABPA. CONCLUSIONS: These findings suggested that serum levels of periostin were up-regulated in ABPA patients, which may be associated with eosinophilic inflammation.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) conducted an observational in Allergic bronchopulmonary aspergillosis and asthma (n=43). Allergic bronchopulmonary aspergillosis (ABPA) vs. Severe asthma with fungal sensitisation (SAFS) was evaluated on Serum levels of periostin (p=< 0.01). Serum periostin levels were significantly higher in patients with allergic bronchopulmonary aspergillosis (85.55 ng/mL) compared to severe asthma with fungal sensitization (50.99 ng/mL; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: